Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar Sells 75,000 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Kush Parmar sold 75,000 shares of the company's stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $6.91, for a total value of $518,250.00. Following the completion of the sale, the director owned 1,113,092 shares in the company, valued at $7,691,465.72. The trade was a 6.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kush Parmar also recently made the following trade(s):

• On Monday, June 30th, Kush Parmar sold 25,000 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.81, for a total value of $170,250.00.

Entrada Therapeutics Stock Up 2.3%

Entrada Therapeutics stock traded up $0.16 during mid-day trading on Wednesday, reaching $7.27. 126,328 shares of the company's stock were exchanged, compared to its average volume of 134,083. The firm has a market capitalization of $275.90 million, a PE ratio of 8.98 and a beta of -0.11. Entrada Therapeutics, Inc. has a one year low of $6.59 and a one year high of $21.79. The business's fifty day simple moving average is $7.98 and its 200 day simple moving average is $10.85.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 14.39% and a return on equity of 5.84%. The firm had revenue of $8.75 million for the quarter, compared to analysts' expectations of $10.98 million. On average, sell-side analysts forecast that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new position in Entrada Therapeutics during the fourth quarter worth about $57,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Entrada Therapeutics by 152.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,750 shares of the company's stock valued at $618,000 after acquiring an additional 21,594 shares during the period. Deutsche Bank AG boosted its holdings in shares of Entrada Therapeutics by 55.5% in the fourth quarter. Deutsche Bank AG now owns 21,740 shares of the company's stock worth $376,000 after acquiring an additional 7,757 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Entrada Therapeutics in the fourth quarter valued at $36,000. Finally, Ameriprise Financial Inc. raised its stake in shares of Entrada Therapeutics by 6.6% during the 4th quarter. Ameriprise Financial Inc. now owns 40,624 shares of the company's stock valued at $702,000 after purchasing an additional 2,517 shares during the period. Hedge funds and other institutional investors own 86.39% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on TRDA shares. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Entrada Therapeutics in a report on Tuesday, May 20th. Wall Street Zen raised Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, June 27th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $25.67.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.